RTW Biotech Opportunities (RTW) has announced that it has made a new investment in series A fundraising of Windward Bio, a Swiss private, clinical-stage drug development company committed to improving outcomes for people living with advanced immunological diseases with an initial focus on severe respiratory conditions. The Series A round raised US$200m in funds which … Continue reading RTW announces Windward Bio and Umoja Biopharma investments